HLA-A*0201 & B2M & KRASG12D (KLVVVGADGV)

HLA-A*0201 & B2M & KRASG12D (KLVVVGADGV) Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag & Avi Tag (1)
Marker
Biotin-labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
HLD-H82E4	Human	HEK293	Biotinylated Human HLA-A*02:01&B2M&KRASG12D (KLVVVGADGV) Complex Protein (Monomer, MALS verified)				In den Warenkorb legen

Gesamtmenge1

HLA-A*0201 & B2M & KRASG12D (KLVVVGADGV) Molekülhintergrund

The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Human HLA-A*0201 KRAS (KLVVVGAGGV) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and KLVVVGAGGV peptide of the KRAS.

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
IBC-0966	IBC-0966	Phase 2 Clinical	SunHo (China) BioPharmaceutical Co Ltd	Neoplasms	Details
BI-765063	OSE-172; BI-765063	Phase 1 Clinical	Ose Immunotherapeutics	Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung	Details
Anzurstobart	BMS-986351; CC-95251	Phase 1 Clinical	Celgene Corp	Myelodysplastic Syndromes; Leukemia, Myeloid, Acute	Details
ADU-1805	ADU-1805	Phase 1 Clinical	Aduro Biotech Inc	Solid tumours; Neoplasms; Neoplasm Metastasis	Details
LM-101	LM-101	Phase 1 Clinical	LaNova Medicines Ltd	Leukemia; Solid tumours; Hematologic Neoplasms; Neoplasms	Details
Q-1801	Q-1801; Q 1801	Phase 1 Clinical	Qiyu Biotechnology (Shanghai) Co Ltd	Solid tumours	Details
Recombinant humanized IgG4 anti-SIRPα antibody（Daiichi Sankyo）	DS-1103a	Phase 1 Clinical	Daiichi Sankyo Co Ltd	Solid tumours; Breast Neoplasms	Details
ELA-026	ELA-026	Phase 1 Clinical	Electra Therapeutics Inc	Lymphohistiocytosis, Hemophagocytic	Details
BYON-4228	BYON-4228	Phase 1 Clinical	Byondis Bv	Solid tumours; Lymphoma	Details
BSI-082	BSI-082	Phase 1 Clinical	Boaoxin Biotechnology(Nanjing) Co Ltd	Hematologic Neoplasms; Solid tumours	Details
BR-105	BR-105; BR105	Phase 1 Clinical	BioRay Pharmaceutical Co Ltd	Neoplasms; Lymphoma, Large B-Cell, Diffuse	Details
[89Zr]Zr- BI-765063(Boehringer Ingelheim)		Phase 1 Clinical	Boehringer Ingelheim Corp	Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Melanoma	Details
TQB-2928	TQB-2928	Phase 1 Clinical		Hematologic Neoplasms; Solid tumours; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute	Details
BI-765080		Phase 1 Clinical	C.H. Boehringer Sohn Ag & Co. Kg		Details
ES-004	ES-004; ES 004-N4; ES 004-B4	Phase 1 Clinical		Solid tumours; Neoplasms	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Relugolix/Estradiol/Norethindrone Acetate	E2/NETA	Approved	Myovant Sciences	MYFEMBREE, RYEQO	United States	Menorrhagia; Leiomyoma	Myovant Sciences	2021-05-26	Pain; Endometriosis; Leiomyoma; Menorrhagia; Uterine Neoplasms	Details
Elagolix/estradiol/norethindrone acetate		Approved	Abbvie Inc	Oriahnn	United States	Menorrhagia	Abbvie Inc	2020-05-29	Menorrhagia	Details